SOLANA BEACH, Calif., July 27, 2012 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (OTC Markets Group: IMMY), a specialty pharmaceutical company developing non-invasive topically delivered products, announced that Stephen G. Austin, CPA has joined its board of directors.
Imprimis Pharmaceuticals, Inc. CEO and Director Mark L. Baum stated, "We are pleased to welcome Mr. Stephen Austin to the Imprimis board of directors. Stephen has distinguished himself as a national and international leader in public company audit, SEC compliance and issues related to Sarbanes-Oxley compliance. Stephen speaks worldwide on corporate governance, Sarbanes-Oxley, and International Financial Reporting Standards matters and has been widely published by the AICPA. Beyond his significant public company financial and accounting experience, Stephen has an impressive record of board service, currently serving as the Audit Chairman for Avanir Pharmaceuticals, Inc. and Red Flag Group (Hong Kong), as well as serving on the Audit Committee for World Trade Center San Diego and board positions with Integra International and Sharp Healthcare Foundation. Stephen also serves as a member of the Strategic Advisory Board for AlliantGroup, a specialty tax advisory firm." Baum added, "As Imprimis continues to progress, Stephen's experience will be a good resource for our board, our management, and will ultimately benefit our shareholders."
About Imprimis Pharmaceuticals, Inc.
Imprimis Pharmaceuticals is a specialty pharmaceutical company developing non-invasive, topically delivered products. Our innovative patented Accudel cream formulation technology is designed to enable highly targeted site specific treatment. Impracor, our lead pain product candidate, utilizes the Accudel platform technology to deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug, through the skin directly into the underlying tissues where the drug exerts its localized anti-inflammatory and analgesic effects. We intend to leverage the Accudel platform technology to expand and create a portfolio of topical products for a variety of indications. The Imprimis Pharmaceuticals, Inc. website is currently under construction and is expected launch in August of 2012.
For More Information
Contact: Mark L. Baum
This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products and to enter into strategic alliances and transactions, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
SOURCE Imprimis Pharmaceuticals, Inc.